The EPS projection of Dolby Laboratories (NYSE:DLB) for quarter ended 2016-09-30 is $0.29. Last week, the EPS forecast was $0.29 against target of $0.29, a month earlier. Two months ago, this estimate was $0.29 versus forecast of $0.29 three months earlier, implying a deviation of 0%.
Dolby Laboratories (NYSE:DLB) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 4.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 0, and 0, correspondingly.
EPS estimate downgrade for Dolby Laboratories (NYSE:DLB) in the preceding 30, 120, 60 and 90 days were 0, 4, 4, and 4, correspondingly.
Dolby Laboratories (NYSE:DLB) EPS target for the quarter closed 2 was $0.29, based on 5 recommendations. As reported on 2016-04-27 the EPS was $0.66. The change was $0.2, implying a percentage deviation of 43.48%. The projections showed a standard deviation of 0.01.
Quarterly Sales Estimates
Dolby Laboratories (NYSE:DLB) yearly sales prediction for the fiscal 2017 stands at $259.043 and the median estimate is at $257.727. Almost 4 analysts issued sales target.
Highest sales target is $263.93 while the lowest target is $256.79 showing standard deviation of 3.335%.
As many as 4 analysts have sales targets revised upside while 4 reduced sales estimates, implying a deviation of 0%.
Last month, 4 revised sales number projection on upside while 4 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 4 hiked sales target and 4 reduced sales forecast. Dolby Laboratories (NYSE:DLB) announced that the deviation in forecast was -4.971%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...